Sign Out
Pharmacology: Pharmacodynamics: Zoledronic acid, a bisphosphonates, which act primarily on bone. Zoledronic acid inhibits bone resorption via actions on osteoclasts and induces osteoclast apoptosis resulting in inhibition of bone degeneration. Zoledronic acid also reduces skeletal calcium release induced by tumors.
Pharmacokinetics: Distribution: After initiating the infusion of zoledronic acid, the plasma concentrations of drug rapidly increased.
Plasma protein binding is low (approximately 23-53%).
Metabolism and elimination: Zoledronate is not metabolized within 24 hours and 39 ±16% of dose is excreted unchanged via the kidney, recovered in the urine and <3% in the feces. Renal clearance is lower in patients with severe renal impairment. Nonrenal clearance is mainly sequestered to bone. The drug is released systemically via bone turnover.
Continue with Google